title: Anti-N-Methyl-D-Aspartate Receptor Encephalitis, an Underappreciated Disease in the Emergency Department.
abstract: Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis is a novel disease discovered within the past 10 years. Antibodies directed at the NMDAR cause the patient to develop a characteristic syndrome of neuropsychiatric symptoms. Patients go on to develop autonomic dysregulation and often have prolonged hospitalizations and intensive care unit stays. There is little literature in the emergency medicine community regarding this disease process, so we report on a case we encountered in our emergency department to help raise awareness of this disease process.
authors.affiliation: UCSD Medical Center, Department of Emergency Medicine, Division of Medical Toxicology, San Diego, California; VA Medical Center, San Diego, California.
authors.forename: Daniel R
authors.initials: DR
authors.lastname: Lasoff
authors.affiliation: UCSD Medical Center, Department of Emergency Medicine, San Diego, California.
authors.forename: Jimmy
authors.initials: J
authors.lastname: Corbett-Detig
authors.affiliation: UCSD Medical Center, Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, San Diego, California.
authors.forename: Rebecca
authors.initials: R
authors.lastname: Sell
authors.affiliation: UCSD Medical Center, Department of Emergency Medicine, San Diego, California.
authors.forename: Matthew
authors.initials: M
authors.lastname: Nolan
authors.affiliation: UCSD Medical Center, Department of Internal Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, San Diego, California.
authors.forename: Gabriel
authors.initials: G
authors.lastname: Wardi
mesh_terms: D060426:Anti-N-Methyl-D-Aspartate Receptor Encephalitis / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D057210:Delayed Diagnosis / Q000009:adverse effects*; D004569:Electroencephalography; D004636:Emergency Service, Hospital; D004830:Epilepsy, Tonic-Clonic / Q000209:etiology*; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D007155:Immunologic Factors / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D010956:Plasmapheresis / Q000379:methods*; D011379:Prognosis; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism*; D000069283:Rituximab / Q000008:administration & dosage; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D007136:Immunoglobulins; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D016194:Receptors, N-Methyl-D-Aspartate; D000069283:Rituximab; D003520:Cyclophosphamide